David Zaccardelli
Principal executive officer pay for David Zaccardelli, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Verona Pharma plc (VRNA) FY2021–FY2024
Beat peersTSR 591% vs peer group -10% over FY2021–FY2024
Turnaround$100 invested moved from behind the peer group ($96.00 vs $99.56) to ahead ($663.43 vs $89.97) over FY2021–FY2024
Aligned: paid up as stock roseCAP $823,718→$19,456,473 while $100 invested went $96.00→$663.43
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2021 | $1.1M | $823,718 |
| FY2022 | $5.2M | $27.6M |
| FY2023 | $6.6M | $558,317 |
| FY2024 | $19.5M | $19.5M |
The company's "$100 invested" index ran $96.00 at FY2021 → $663.43 by FY2024 — an annualized return of 90.5%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 90.5%/yr at VRNA ( FY2021–FY2024). See the CEO track-record ranking for context.